Gsk (GSK) Total Debt (2009 - 2026)

Gsk (GSK) has 18 years of Total Debt data on file, last reported at -$216.2 million in Q3 2026.

• For the quarter ending Q3 2026, Total Debt changed N/A year-over-year to -$216.2 million; the trailing twelve-month figure through Sep 2026 stood at -$216.2 million (changed N/A YoY), and the FY2025 full-year result was -$30.7 billion, down 4.11% from the prior year.
• Total Debt was -$216.2 million for Q3 2026 at Gsk, up from -$31.7 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of -$216.2 million in Q3 2026 to a low of -$34.7 billion in Q2 2022.
• A 5-year average of -$29.1 billion and a median of -$30.7 billion in 2025 frame the typical range for Total Debt.
• Across the five-year window, Total Debt soared 54.03% in 2022 and tumbled 62.62% in 2023, its largest moves.
• Gsk's Total Debt stood at -$31.4 billion in 2022, then climbed by 6.59% to -$29.3 billion in 2023, then retreated by 1.08% to -$29.6 billion in 2024, then fell by 3.69% to -$30.7 billion in 2025, then soared by 99.3% to -$216.2 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were -$216.2 million in Q3 2026, -$31.7 billion in Q2 2026, and -$32.8 billion in Q1 2026.